Company news
Algorae Pharmaceuticals Limited (ASX:1AI) news
Algorae Pharmaceuticals Limited news releases on 6ix. Latest, Aug 31, 2026: Appendix 4E and 2026 Annual Report
Press releases & updates
Appendix 4E and 2026 Annual Report
August 31, 2026
Quarterly Activities Report/Appendix 4C Cashflow Statement
July 30, 2026
Peter Mac Testing Validates AlgoraeOS v2
July 2, 2026
Updated - NSW Health Public Hospital Supply Contract
July 1, 2026
Algorae Awarded NSW Health Public Hospital Supply Contract
June 30, 2026
Algorae Expands AI Drug Combination Pipeline
May 17, 2026
1AI Executes License & Supply Agreement with Torrent Pharma
May 5, 2026
Algorae and Zydus Enter Exclusive Commercial Agreement
April 27, 2026
Algorae Pharmaceuticals Ltd Raises $3.9m
April 2, 2026
TGA Accepts Initial Registration Dossier for Evaluation
April 1, 2026
Peter Mac Partners with Algorae on AI Validation
March 29, 2026
Half Year Report and Appendix 4D
February 27, 2026
Algorae Signs License and Supply Agreement with Cadila
February 8, 2026
Quarterly Activities Report /Appendix 4C Cash Flow Statement
January 27, 2026
$3 million Debt Facility Secured with ScotPac
January 20, 2026
AlgoraeOS v2 Identifies 90 Drug Combination Candidates
December 11, 2025
Algorae Receives $384,466.78 R&D Tax Incentive Refund
December 9, 2025
Peter Mac Testing Validates AlgoraeOS - v2 Launched
December 4, 2025
Algorae Signs Distribution Agreement with Dr. Reddy's
November 26, 2025
Loyalty Options Offer
November 16, 2025
Prospectus - Loyalty Options Offer
November 16, 2025
AlgoraeOS Version 2 AI Platform Launched
November 9, 2025
Algorae Signs Binding Term Sheet with Cadila Pharmaceuticals
October 19, 2025
Algorae Signs Exclusive License Agreement with Sakar
September 22, 2025
Annual Report and Appendix 4E
August 28, 2025
Algorae Receives A$318,771 R&D Cash Rebate from ATO
June 5, 2025
Peter Mac Partners with Algorae on AI Drug Targets
May 7, 2025
Algorae Receives A$451,359 R&D Cash Rebate from ATO
March 30, 2025
Half Yearly Report Announcement and Appendix 4D
February 26, 2025
Significant Cardioprotection Qualities in AI-168 Studies
November 28, 2024
24 New AI-Generated Drug Targets
November 20, 2024
AlgoraeOS Artificial Intelligence Platform Launched
September 23, 2024
Positive results from AI-116 in vitro studies
July 30, 2024
Artificial Intelligence Platform Update
March 7, 2024
Response to ASX Price Query
February 20, 2024
NTCELL Project Update
February 14, 2024
Quarterly Activities Report/Appendix 4C Cash Flow Statement
January 29, 2024
Agreement with HL Pharma Addendum
January 4, 2024
Algorae to list existing Option series on ASX
December 5, 2023
1AI commences AI-168 pre-clinical studies
November 22, 2023
Addendum to September Quarterly Report
November 21, 2023
CSIRO Grant for Artificial Intelligence Platform
October 30, 2023
Quarterly Activities/Appendix 5B Cash Flow Report
October 26, 2023
LCT commences AI-116 pre clinical studies
August 31, 2023
Quarterly Activities/Appendix 4C Cash Flow Report
July 27, 2023
Patent application over AI-116 for Dementia filed
July 25, 2023
LCT Announces Shortfall Completion Notice
May 3, 2023
Rights Issue Prospectus
March 20, 2023
APeT Cleansing Announcement
March 10, 2023
Pause in Trading
March 10, 2023